循环肿瘤DNA在大B细胞淋巴瘤接受阿基仑赛治疗后为PET增加特异性
这项前瞻性多中心样本采集研究评估复发/难治性大B细胞淋巴瘤患者接受阿基仑赛后1个月代谢活跃病灶的意义,通过分析PET总代谢肿瘤体积(MTV)与血浆循环肿瘤DNA(ctDNA)的关系,发现1个月时ctDNA与MTV不相关但在3个月时相关,模型提示1个月PET上非进展性高代谢病灶代表持续治疗反应。
要点
- 基线扫描至阿基仑赛输注中位时间33天(范围1-137天),全部57例患者。
- 41例在输注33天内成像或之前成像但未桥接治疗的患者基线相关性更强(rs=0.61,P<.0001)vs 全部患者(rs=0.38,P=.004)。
- 排除无可测残留病灶的完全缓解患者后,1个月ctDNA与MTV不相关(rs=0.28,P=.11),3个月相关(rs=0.79,P=.0007)。
核心结论
- 1个月PET上非进展性高代谢病灶代表持续治疗反应,其组成可通过同时检测ctDNA来阐明。
研究设计与样本
- 前瞻性多中心样本采集研究,纳入57例接受阿基仑赛治疗的复发/难治性大B细胞淋巴瘤患者,回顾性计算基线、1个月和3个月PET的MTV,并在阿基仑赛前后检测ctDNA。
主要发现
- 全部57例患者基线扫描至阿基仑赛输注中位时间33天(范围1-137天)。
- 41例在输注33天内成像或之前成像但未桥接治疗的患者基线相关性rs=0.61(P<.0001),全部患者rs=0.38(P=.004)。
- 排除无可测残留病灶的完全缓解患者后,1个月ctDNA与MTV不相关(rs=0.28,P=.11),3个月相关(rs=0.79,P=.0007)。
- 纳入ctDNA和炎症作为MTV一部分的肿瘤动力学模型再现了1个月影像学阳性扫描患者的结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined the meaning of metabolically active lesions on 1-month restaging nuclear imaging of patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel (axi-cel) by assessing the relationship between total metabolic tumor volume (MTV) on positron emission tomography (PET) scans and circulating tumor DNA (ctDNA) in the plasma. In this prospective multicenter sample collection study, MTV was retrospectively calculated via commercial software at baseline, 1, and 3 months after chimeric antigen receptor (CAR) T-cell therapy; ctDNA was available before and after axi-cel administration. Spearman correlation coefficient (rs) was used to study the relationship between the variables, and a mathematical model was constructed to describe tumor dynamics 1 month after CAR T-cell therapy. The median time between baseline scan and axi-cel infusion was 33 days (range, 1-137 days) for all 57 patients. For 41 of the patients with imaging within 33 days of axi-cel or imaging before that time but no bridging therapy, the correlation at baseline became stronger (rs, 0.61; P < .0001) compared with all patients (rs, 0.38; P = .004). Excluding patients in complete remission with no measurable residual disease, ctDNA and MTV at 1 month did not correlate (rs, 0.28; P = .11) but correlated at 3 months (rs, 0.79; P = .0007). Modeling of tumor dynamics, which incorporated ctDNA and inflammation as part of MTV, recapitulated the outcomes of patients with positive radiologic 1-month scans. Our results suggested that nonprogressing hypermetabolic lesions on 1-month PET represent ongoing treatment responses, and their composition may be elucidated by concurrently examining the ctDNA.
引用
- Dean EA, Kimmel GJ, Frank MJ, et al. Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2023. PMID: 37126659. doi:10.1182/bloodadvances.2022009426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。